New imaging technique has shown that many cases of prostate cancer may be more advanced than conventional imaging suggests. Read on!

EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first ...

Sir Chris Hoy hailed the fundraising as a “huge step forward” in the fight to make change. "The huge sum Paddy Power are ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Penile Cancer.

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...